Imaging metastatic bone disease from carcinoma of the prostate

C. Messiou; G. Cook; N. M. deSouza

doi:10.1038/sj.bjc.6605334

Imaging metastatic bone disease from carcinoma of the prostate

C. Messiou, G. Cook, N. M. deSouza

Imaging and Biomedical Engineering

Research output: Contribution to journal › Article › peer-review

88 Citations (Scopus)

Abstract

Imaging bone metastases from prostate cancer presents several challenges. The lesions are usually sclerotic and appear late on the conventional X-ray. Bone scintigraphy is the mainstay of lesion detection, but is often not suitable for assessment of treatment response, particularly because of a 'flare' phenomenon after therapy. Magnetic resonance imaging is increasingly used in assessment, and newer techniques allow quantitation. In addition to (18)F-fluorodeoxyglucose ((18)FDG), newer PET isotopes are also showing promise in lesion detection and response assessment. This article reviews the available imaging modalities for evaluating prostatic bony metastases, and links them to the underlying pathological changes within bone lesions. British Journal of Cancer (2009) 101, 1225-1232.

Original language	English
Pages (from-to)	1225-1232
Number of pages	8
Journal	BJC: British Journal of Cancer
Volume	101
Issue number	8
Early online date	29 Sept 2009
DOIs	https://doi.org/10.1038/sj.bjc.6605334
Publication status	Published - 20 Oct 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/sj.bjc.6605334

Cite this

@article{e9d5b419f7eb4e1a98adf51f403c8bf7,

title = "Imaging metastatic bone disease from carcinoma of the prostate",

abstract = "Imaging bone metastases from prostate cancer presents several challenges. The lesions are usually sclerotic and appear late on the conventional X-ray. Bone scintigraphy is the mainstay of lesion detection, but is often not suitable for assessment of treatment response, particularly because of a 'flare' phenomenon after therapy. Magnetic resonance imaging is increasingly used in assessment, and newer techniques allow quantitation. In addition to (18)F-fluorodeoxyglucose ((18)FDG), newer PET isotopes are also showing promise in lesion detection and response assessment. This article reviews the available imaging modalities for evaluating prostatic bony metastases, and links them to the underlying pathological changes within bone lesions. British Journal of Cancer (2009) 101, 1225-1232.",

author = "C. Messiou and G. Cook and deSouza, {N. M.}",

note = "M1 - 8 Times Cited: 7",

year = "2009",

month = oct,

day = "20",

doi = "10.1038/sj.bjc.6605334",

language = "English",

volume = "101",

pages = "1225--1232",

journal = "BJC: British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "8",

}

TY - JOUR

T1 - Imaging metastatic bone disease from carcinoma of the prostate

AU - Messiou, C.

AU - Cook, G.

AU - deSouza, N. M.

N1 - M1 - 8 Times Cited: 7

PY - 2009/10/20

Y1 - 2009/10/20

N2 - Imaging bone metastases from prostate cancer presents several challenges. The lesions are usually sclerotic and appear late on the conventional X-ray. Bone scintigraphy is the mainstay of lesion detection, but is often not suitable for assessment of treatment response, particularly because of a 'flare' phenomenon after therapy. Magnetic resonance imaging is increasingly used in assessment, and newer techniques allow quantitation. In addition to (18)F-fluorodeoxyglucose ((18)FDG), newer PET isotopes are also showing promise in lesion detection and response assessment. This article reviews the available imaging modalities for evaluating prostatic bony metastases, and links them to the underlying pathological changes within bone lesions. British Journal of Cancer (2009) 101, 1225-1232.

AB - Imaging bone metastases from prostate cancer presents several challenges. The lesions are usually sclerotic and appear late on the conventional X-ray. Bone scintigraphy is the mainstay of lesion detection, but is often not suitable for assessment of treatment response, particularly because of a 'flare' phenomenon after therapy. Magnetic resonance imaging is increasingly used in assessment, and newer techniques allow quantitation. In addition to (18)F-fluorodeoxyglucose ((18)FDG), newer PET isotopes are also showing promise in lesion detection and response assessment. This article reviews the available imaging modalities for evaluating prostatic bony metastases, and links them to the underlying pathological changes within bone lesions. British Journal of Cancer (2009) 101, 1225-1232.

U2 - 10.1038/sj.bjc.6605334

DO - 10.1038/sj.bjc.6605334

M3 - Article

SN - 0007-0920

VL - 101

SP - 1225

EP - 1232

JO - BJC: British Journal of Cancer

JF - BJC: British Journal of Cancer

IS - 8

ER -

Imaging metastatic bone disease from carcinoma of the prostate

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this